Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
51 hedge funds and large institutions have $4.03M invested in Nymox Pharmaceutical Corp in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 21 closing their positions.
200% more call options, than puts
Call options by funds: $60K | Put options by funds: $20K
14% less funds holding
Funds holding: 59 → 51 (-8)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
70% less capital invested
Capital invested by funds: $13.3M → $4.03M (-$9.28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$568K |
| 2 |
E
Ergoteles
New York
|
+$345K |
| 3 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$280K |
| 4 |
HF
HRT Financial
New York
|
+$223K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$137K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.28M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.16M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$826K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$485K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$453K |
NYMX Hedge Fund Activity: Q2 2021 in Review
51 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q2 2021, worth a combined $4.03M — down 70% from $13.3M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of NYMX and 13 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was Millennium Management, adding an estimated $568K. The largest seller was BlackRock, cutting an estimated $3.28M.
- 51 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q2 2021, down from 59 in Q1 2021.
- Funds reported $4.03M of Nymox Pharmaceutical Corp stock for Q2 2021, down 70% quarter-over-quarter.
- 13 funds opened new Nymox Pharmaceutical Corp positions in Q2 2021 and 21 closed out, a net change of -8 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q2 2021 was Millennium Management, an estimated $568K added.
- The largest Nymox Pharmaceutical Corp seller in Q2 2021 was BlackRock, an estimated $3.28M sold.
Based on aggregated 13F filings for Q2 2021.